Article
Envision Pharma Group
The PACE of Technology in Medical Affairs-Tools of the Trade
Summary
In this episode, Matt Lewis joins Tom Caravela to delve into the evolving landscape of AI in medical affairs, focusing on its current state in 2024. They explore practical applications of AI for Medical Science Liaisons (MSLs), highlighting the efficiency and benefits it brings to MSL teams. The discussion covers customizing AI tools for internal use and their potential applications in field medical. Matt and Tom also consider AI's pervasive future and its subtle integration into daily operations. The episode concludes with thoughts on AI's potential to address global challenges, offering listeners insights into harnessing AI for enhanced productivity and impact.
My guest this week is Matt Lewis, Global Chief Artificial and Augmented Intelligence Officer at Inizio Medical who discusses AI tools and the pace of technology in Medical Affairs.
Learn more about…
👉 What will be different tech-wise for MSLs in 2024, versus 2023
👉 How should companies be using AI in a field medical environment
👉 What should MSLs be doing with AI this year
👉 How will managers implement new AI programs
👉 The pace and how quickly pharma will move with technology advancements
AI in medical affairs, Medical Science Liaisons AI, AI tools in pharma, future of AI in healthcare, AI integration in medical operations
Related Topics
You May Also Like
Envision Pharma Group
Podcast
MSL Talk: Tom Caravela, Paul Ward
How Medical Affairs Professionals Should Engage with Digital Opinion Leaders
Podcast
MSL Talk: Tom Caravela, Patrina Pellett
Fierce Pharma Engage 2025 - RECAP
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS